Interpace Biosciences, Inc.
IDXGD
$6.98
-$0.02-0.29%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -78.09% | -96.82% | 2,387.05% | 242.34% | -138.86% |
| Total Depreciation and Amortization | 4.89% | 1.81% | 4.74% | 6.03% | 4.74% |
| Total Amortization of Deferred Charges | -- | -- | 0.00% | 6.67% | 36.36% |
| Total Other Non-Cash Items | 0.71% | 101.32% | -19,052.68% | -47.66% | 2,240.00% |
| Change in Net Operating Assets | 38.67% | -300.42% | -31.54% | -6.01% | 221.39% |
| Cash from Operations | -65.37% | -86.76% | 10.32% | 272.69% | -57.89% |
| Capital Expenditure | 59.57% | -271.05% | 67.52% | 41.79% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 59.57% | -271.05% | 67.52% | 41.79% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -11.11% | 10.00% | 33.33% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | -- | -- | -13.11% | 11.15% | 32.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -71.13% | -86.88% | 17.48% | 232.71% | -161.89% |